ProTom International Introduces Radiance 330-C: A More Flexible and Accessible Proton Therapy Solution

Trending...
WOBURN, Mass., Sept. 27, 2024 ~ ProTom International, a leading provider of compact proton therapy technology, has announced the launch of its latest innovation in cancer treatment - the Radiance 330-C Proton Therapy SystemTM. This new system is set to revolutionize the field of proton therapy with its compact and modular design, making it more accessible and cost-effective for healthcare providers.

The Radiance 330-C Single Room Solution offers a fixed-beam room configuration that can be easily integrated into existing radiation oncology departments. This allows for single or multiple-room capabilities within or adjacent to existing Linac vaults, providing flexibility and convenience for healthcare providers. When combined with Leo Cancer Care's upright patient positioning and imaging system, the Radiance 330-C offers gantry-less proton therapy without compromising on treatment capability.

One of the key features of this new system is its Fidelity™ pencil beam scanning technology, which allows for precise dose sculpting. The system also includes an upright patient positioning system and diagnostic quality CT at the treatment isocenter, enabling real-time adaptive therapy. The stationary beam delivery system improves reliability, beam parameters, and accuracy while reducing maintenance costs. Additionally, it boasts a compact synchrotron particle accelerator that can deliver a clinical treatment energy range from 70 MeV to 250 MeV with a capacity of up to 330 MeV for future deployment of proton imaging.

More on Boston Chron
Paul Tso, CEO of ProTom International expressed his excitement about the launch of Radiance 330-C: "We are thrilled to introduce this groundbreaking technology to the world. With Leo's Upright Positioning and Imaging System, Radiance 330-C becomes even more accessible to those who need it but are constrained by space and resources. As promised by ProTom, we are dedicated to providing healthcare providers with a modular, compact, and economically viable proton therapy solution."

Stephen Towe, CEO of Leo Cancer Care also shared his enthusiasm about this partnership: "Our mission has always been to make Proton Therapy available to as many people as possible. By offering our solution in various configurations, we are taking a significant step towards achieving this goal. This partnership with ProTom International showcases the industry's commitment to innovation and breaking down barriers to better care."

It is important to note that the Radiance 330-C Proton Therapy System is not yet available for clinical use. However, with its advanced technology and cost-effective design, it is expected to have a significant impact on the field of cancer treatment once it becomes available.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on Boston Chron